Neurology
NeuroSense Reports Clean Safety Profile From Phase 2 PrimeC Study In Alzheimer’s Disease
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for&nbs...
December 24, 2025 | News
UK Hospitals Adopt AI Tool MEMORI To Strengthen Early Detection Of Hospital Acquired Infections
Sanome, the health tech company behind MEMORI, an AI-powered clinical decision support tool that helps clinicians detect hospital-acquired infections (HAIs...
December 18, 2025 | News
South Korea Takes A Major Step Toward Blood Based Alzheimer’s Diagnosis With Simoa Platform Approval
Quanterix Corporation (NASDAQ: QTRX), a U.S.-based biotechnology company specializing in ultrasensitive biomarker detection, and its clinical diagnostics b...
December 12, 2025 | News
Otsuka Advances Centanafadine With FDA Filing To Bring a First in Class ADHD Therapy to Children, Adolescents, and Adults
Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents, and adults. It is a first-in-class norepinephrine, dop...
November 26, 2025 | News
Aspen Neuroscience Secures $115 Million Series C to Advance Personalised Cell Therapy for Parkinson’s Disease
Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, announced the closing of a $115 millio...
November 21, 2025 | News
ReviR Therapeutics Wins CIRM Grant to Advance First in Class Dual Target Therapy for Huntington’s Disease
ReviR Therapeutics, a biotech company focused on developing innovative treatments for neurogenetic diseases, announced that it has been awarded a $4....
November 21, 2025 | News
Akeso Receives NMPA Clearance to Initiate Clinical Trials for China’s First Bispecific Antibody for Alzheimer’s Disease
Akeso, Inc. (HKEX: 9926.HK) announced that its AK152, a novel bispecific antibody targeting both amyloid-beta (Aβ) and blood-brain barrier (BBB) expre...
November 18, 2025 | News
Muna Therapeutics Doses First Subjects in Phase 1 Trial of TREM2 Agonist MNA-001 for Alzheimer’s Disease
MNA-001 has best-in-class potential based on preclinical data demonstrating ability to significantly reduce neurotoxic amyloid burden and reprogram microgl...
November 11, 2025 | News
Cellectricon Launches Neurotoxicity Testing Services to Strengthen Early Safety Assessment in Neuroscience Drug Discovery
Cellectricon, a services provider dedicated to advancing neuroscience drug discovery, announced the launch of its new Neurotoxicity Testing Services; expan...
October 31, 2025 | News
METiS TechBio’s AI-Designed MTS-004 Meets Phase III Success in China, Targeting Pseudobulbar Affect
MTS-004 Poised to Fill an Unmet Need in the Treatment of Pseudobulbar Affect (PBA) METiS TechBio, a global leader in AI-driven nanodelivery and formulatio...
October 24, 2025 | News
Lundbeck’s Bexicaserin Receives Breakthrough Therapy Designation in China for Severe Childhood Epilepsies
Accelerated pathway underscores urgent need for innovative solutions for patients with devastating, childhood-onset epilepsies Novel 5HT2C mechanism des...
October 14, 2025 | News
Ono Pharma Reports Positive Phase 2 Signals for ONO-2808 in Multiple System Atrophy
Efficacy signals were observed in an interim analysis of a Phase 2 clinical trial for ONO-2808, a S1P5 receptor agonist Phase 2 clinical trial was con...
October 13, 2025 | News
ExQor Technologies Prepares for Clinical Trials of Regenerative Platform Aiming to Reverse Alzheimer’s Damage
ExQor Technologies, a Boston MA based biotechnology company, is preparing for clinical trials for its proprietary brain regenerative medicine pla...
October 06, 2025 | News
HKUST Uncovers Genetic Variant Driving Alzheimer’s Risk Among Ethnic Chinese
A landmark study conducted by The Hong Kong University of Science and Technology (HKUST) has demonstrated that a genetic variant, TREM2 ...
October 06, 2025 | News
Most Read
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
